KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash from Operations: 2009-2024

Historic Cash from Operations for Biocryst Pharmaceuticals (BCRX) over the last 16 years, with Dec 2024 value amounting to -$52.0 million.

  • Biocryst Pharmaceuticals' Cash from Operations fell 6.75% to -$14.8 million in Q4 2015 from the same period last year, while for Dec 2015 it was -$13.1 million, marking a year-over-year increase of 65.98%. This contributed to the annual value of -$52.0 million for FY2024, which is 45.32% up from last year.
  • As of FY2024, Biocryst Pharmaceuticals' Cash from Operations stood at -$52.0 million, which was up 45.32% from -$95.1 million recorded in FY2023.
  • In the past 5 years, Biocryst Pharmaceuticals' Cash from Operations registered a high of -$52.0 million during FY2024, and its lowest value of -$161.8 million during FY2022.
  • For the 3-year period, Biocryst Pharmaceuticals' Cash from Operations averaged around -$103.0 million, with its median value being -$95.1 million (2023).
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 50.82% in 2020, then soared by 45.32% in 2024.
  • Yearly analysis of 5 years shows Biocryst Pharmaceuticals' Cash from Operations stood at -$135.1 million in 2020, then dropped by 5.22% to -$142.2 million in 2021, then dropped by 13.85% to -$161.8 million in 2022, then skyrocketed by 41.22% to -$95.1 million in 2023, then spiked by 45.32% to -$52.0 million in 2024.